Stelic Institute Presented Novel Research Results at Keystone Symposia

Stelic Institute & Co., a Tokyo-based bio-venture company specializing in regenerative medicine, has announced Dr. Hiroyuki Yoneyama, Chairman & Representative Director of Stelic, with Dr. Yoshiro Kai, a visiting researcher of Stelic (MD, Nara Medical University in Japan) presented the basic research results of novel therapy for pulmonary fibrosis at the Keystone Symposia “Molecular Mechanisms of Fibrosis: From Bench to Bedside” on March 11 - 15, 2007 in Tahoe city, California.

Keystone Symposia develops and administers international symposia of the highest quality on topics of interest to researchers in biology, medical science and agriculture with the goal of facilitating interdisciplinary information exchange for the benefit of society.
In the meeting of Molecular Mechanisms of Fibrosis, academic researchers, clinicians, and members of the pharmaceutical industry were brought together to present/discuss the most recent advances in the field and to identify common mechanistic themes of tissue fibrogenesis in various tissue systems (*) (causes of 45% of all deaths in the western world).

World-class 250 researchers including Dr. Thomas A. Wynn, and Dr. Robert M. Strieter, leading researchers in this field, attended this meeting, and discussed the latest research for four days. A total of three Japanese research groups attended this meeting including one group of U.S. residents.

“Our presentation was successful to gather a lot of attention of researchers in the world. This meeting was beneficial for us to provide the novelty of Stelic research and to communicate with the world’s greatest researchers,” said Dr. Yoneyama. “This gets our hope up to the success of our planned symposium at Los Angeles, California in the future.”

(*)Fibrosis affects nearly all tissues and organs, and causes such as interstitial lung diseases, liver cirrhosis, kidney disease, heart disease, and systemic sclerosis.